The lung cancer therapeutics market was valued at USD 41.8 billion in 2025, is projected to reach USD 141.2 billion by 2036 and is forecast to register an 11.7% CAGR between 2026 and 2036, creating an incremental opportunity of USD 94.5 billion. In 2026, targeted therapies hold 91.2% of the drug class category.